Mirtazapin Heumann (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes 5‑HT2 and 5‑HT3 receptors, which together boost serotonergic activity while reducing certain serotonin‑related side effects.

The appropriate dose of Mirtazapin Heumann is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines.

Safety of mirtazapine in pregnancy has not been definitively established, and it is generally recommended only if the potential benefit outweighs the risk. Breastfeeding is not advised unless the prescriber determines that benefits to the mother surpass potential risks to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapin Heumann should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure they are out of reach of children.

The medication is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include the potential for suicidal thoughts or behavior, especially early in treatment, serotonin syndrome when combined with other serotonergic drugs, severe neutropenia or agranulocytosis, and rare severe skin reactions such as Stevens‑Johnson syndrome.

Patients with known hypersensitivity to mirtazapine or any excipients, those currently taking monoamine oxidase inhibitors, or individuals with a history of severe neutropenia should avoid this medication. Additionally, caution is advised for patients with uncontrolled hypertension or severe liver impairment.